10 jul: UIEs aktietilbagekøbsprogram
10 jul: LR Realkredit A/S - Ekstraordinære indfrielser (CK93)
10-07-2017 11:04:21

Share buy-back week 27/2017

Announcement             

10 July 2017

Coloplast – transactions in connection with share buy-back programme

As mentioned in Announcement No. 2/2017 Coloplast has initiated the second part of the share buy-back programme totalling up to DKK 1bn. This part of the programme of DKK500m is expected to take place from 27 February, 2017 to 28 August, 2017.

The buy-back programme will be structured in accordance with Article 5 of Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and Regulation 2016/1052, also referred to as the "Safe Harbour" rules, which ensure that the company is protected against violation of insider legislation in connection with the buyback programme.

The following transactions have been executed during 3 – 7 July 2017:

Date

Number of shares

Buying price

Amount DKK

3 July 2017

45,000

543.87

24,474,316.50

4 July 2017

10,000

541.70

5,417,047.00

5 July 2017

28,384

539.25

15,306,040.78

6 July 2017

16,790

538.34

9,038,782.33

7 July 2017

3,374

535.91

1,808,163.38

Accumulated until now under the programme

801,029

536.37

429,647,014.27

Henceforth, Coloplast owns 3,705,272 treasury B shares of DKK 1 equal to 1.72% of the company’s total share capital.

 

Kind regards,

Investor Relations

Coloplast A/S

Tel. +45 4911 1800

 

For further information, please contact

Investors and analysts                                       

Ellen Bjurgert

Director, Investor Relations

Tel. +45 4911 1800/+45 4911 3376

Email: dkebj@coloplast.com

 

Rasmus Sørensen

Sr. Manager, Investor Relations

Tel. +45 4911 1800/ +45 4911 1786

Email: dkraso@coloplast.com

                                                                              

Press and the media                                          

Dennis Kaysen

Director, Corp. Communication

Tel. 4911 2608

Email: dkdk@coloplast.com

 

This announcement is available in a Danish and an English language version. In the event of discrepancies, the Danish version shall prevail.

Coloplast develops products and services that make life easier for people with very personal and private medical conditions. Working closely with the people who use our products, we create solutions that are sensitive to their special needs. We call this intimate healthcare.

Our business includes ostomy care, urology and continence care and wound and skin care. We operate globally and employ more than 11,000 people.

The Coloplast logo is a registered trademark of Coloplast A/S. © 2017-07 All rights reserved Coloplast A/S, 3050 Humlebæk, Denmark.

Relateret indhold
17 apr - 
Onsdagens aktier: Coloplast faldt, men GN faldt mest
17 apr - 
FDA-påbud skærer 25 mio. dollar af toplinjen hos Colopl..
17 apr - 
Middag: Coloplast sætter sig mere end markedet efter FD..
Vedhæftet fil 1: Sharebuyback_10072017.pdf
Vedhæftet fil 2: Transaction_data_week_27.pdf
Del

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
Ingen indlæg

Episode 15 - Lars Seier Christensen ser FC Porto som model for FCK

11-04-2019 15:15:13
I denne episode er finansmanden Lars Seier Christensen gæst i studiet hos Euroinvestors Lars Christensen til en snak om investeringer i sports- og fritidsindustrien med afsæt i Lars Seier Christensens nylige investering i Parken Sport & Entertainment - virksomheden bag fodboldklubben FC København.I samtalen fremhæver Lars Seier Christensen blandt andet den portugisiske fodklub FC Porto som en mode..

Aktier/tendens: Panalpina-tal kan give DSV-fokus i rolig handelsstart

17-04-2019 07:48:02
DSV kan komme i fokus onsdag, efter at schweiziske Panalpina, som den danske transportgigant er ved at overtage, fra morgenstunden har præsenteret regnskabstal, der var bedre end ventet blandt analytikerne.I årets første kvartal nåede Panalpina en omsætning på 1,49 mia. schweizerfranc, svarende til 9,8 mia. kr., hvor der blandt analytikere adspurgt af Bloomberg News var ventet en omsætning på 1,45..

Genmab-partner leverer bedre end ventet: Darzalex skuffer lidt

16-04-2019 12:58:48
Den amerikanske medicinalvirksomhed Johnson & Johnson, der samarbejder med danske Genmab omkring salg af kræftmidlet Darzalex, har leveret et bedre end ventet regnskab for første kvartal.Til gengæld ser det globale salg af Darzalex ud til at skuffe, da det i første kvartal endte på 629 mio. dollar. Til sammenligning havde Sydbanks senioranalytiker Søren Løntoft Hansen ventet et globalt salg på 660..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge

Relaterede aktiekurser

Coloplast B A/S 685,40 -1,7% Fald i aktiekurs
Coloplast 108,95 0,0% Fald i aktiekurs

Copyright Berlingske Media 2019  Handelsbetingelser  |  Cookiedeklaration  |  Cookie- og Privatlivspolitik  |  Ophavsret og vilkår
Aktieinformation leveres af Morningstar.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
18. april 2019 22:42:10
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20190410.2 - EUROWEB5 - 2019-04-18 22:42:10 - 2019-04-18 22:42:10 - 1 - Website: OKAY